Adjuvant Treatment with Yupingfeng Formula for Recurrent Respiratory Tract Infections in Children: A Meta-analysis of Randomized Controlled Trials

Song, Tao; Hou, Xiaoming; Yu, Xiaohui; Wang, Zhen; Wang, Ruiren; Li, Yanling; Hu, Dan; Wang, Xiaohong; Zhang, Xiao; Sui, Yong Gang; Zhu, Chunhong; Wang, Jing

doi:10.1002/ptr.5628

Cited by 23 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although lots of researches had confirmed the efficacy of YPFS, more mechanisms by which YPFS inhibit inflammatory response should be fully elucidated ( Chen et al, 2014 ; Song et al, 2016 ). In this study, we used network pharmacological analysis to investigate the mechanisms of YPFS acting on asthma.…”

Section: Discussionmentioning

confidence: 99%

Yupingfeng San Inhibits NLRP3 Inflammasome to Attenuate the Inflammatory Response in Asthma Mice

et al. 2017

View full text Add to dashboard Cite

Yupingfeng San (YPFS) is a representative Traditional Chinese Medicine (TCM) formula with accepted therapeutic effect on Asthma. However, its action mechanism is still obscure. In this study, we used network pharmacology to explore potential mechanism of YPFS on asthma. Nucleotide-binding oligomerization domain (NOD)-like receptor pathway was shown to be the top one shared signaling pathway associated with both YPFS and asthma. In addition, NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome was treated as target protein in the process of YPFS regulating asthma. Further, experimental validation was done by using LPS-stimulated U937 cells and ovalbumin (OVA)-sensitized BALB/c mice model. In vitro experiments showed that YPFS significantly decreased the production of TNF-α and IL-6, as well as both mRNA and protein levels of IL-1β, NLRP3, Caspase-1 and ASC in LPS-stimulated U937 cells. In vivo experiment indicated that YPFS treatment not only attenuated the clinical symptoms, but also reduced inflammatory cell infiltration, mucus secretion and MUC5AC production in lung tissue of asthmatic mice. Moreover, YPFS treatment remarkably decreased the mRNA and protein levels of IL-1β, NLRP3, Caspase-1 and ASC in lung tissue of asthmatic mice. In conclusion, these results demonstrated that YPFS could inhibit NLRP3 inflammasome components to attenuate the inflammatory response in asthma.

show abstract

Section: Discussionmentioning

confidence: 99%

Yupingfeng San Inhibits NLRP3 Inflammasome to Attenuate the Inflammatory Response in Asthma Mice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…One of the reasons may due to the underlying pathogenesis of AD recurrence is still unclear. YPFS as a potent TCM against allergic disorder, applied in remission phase has been proven efficient through thousands of years of Chinese history [11,12]. Revealing the pharmacological mechanism of YPFS against AD recurrence, may help us to improve understanding the mechanisms of AD recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…Accumulated evidence recently points to the important role of AS-IV in regulating Toll-like receptors (TLRs)-mediated NF-κB pathway to exert its pharmacological effects [8][9][10]. Yu-Ping-Feng-San (YPFS), a well-known traditional Chinese medicine (TCM), is clinically applied for allergic disorders with reduced relapse rates and recurring severity [11,12]. Our previous study elucidated that YPFS attenuated recurrent allergic inflammation of AD by repairing epithelial barrier defects in remission phase [13].…”

mentioning

confidence: 99%

Astragaloside IV prophylactic administration relieves recurrent allergic atopic dermatitis

Zheng

Yu²,

Wei

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundAtopic dermatitis (AD) is a common allergic inflammatory skin disease with high relapse rates and recurring severity. However, the underlying pathogenesis of AD recurrence is still unclear. Our previous study reported Astragaloside IV (AS-IV) administration in sensitization stage ameliorated the allergic inflammation of AD. In this study, we aimed to evaluate the efficacy of AS-IV which prophylactic applied in remission phase of AD and to investigate the underlying mechanisms.MethodsThe efficacy of AS-IV with prophylactic administration in remission phase of AD was evaluated in a fluorescein isothiocyanate (FITC)-induced AD relapse (AD-Re) model. Production of IL-4, IL-5 IL-13, IFN-γin mice ear tissues, IgE in serum were measured by ELISAs. Pharmacokinetic profile of AS-IV was assessed by HPLC-MS. Protein and gene expression levels of TLRs and NF-κB were detected by WB and qRT-PCR, respectively. Results: Prophylactic administration in remission phase of AD, AS-IV attenuated ear swelling, inflammatory cell infiltration, IgE production of ear homogenates in AD-Re mice. Levels of T helper (Th)2 cytokines including IL-4, IL-5, IL-13 but not Th1 cytokine IFN-γin AD-Re mice were inhibited remarkably with AS-IV preventively treatment. In addition, a different pharmacokinetic profile of AS-IV was observed as applied in remission phase. Moreover, AS-IV prophylactic administration decreased the gene expression of NF-κB and TLR8 in AD-Re mice. Consistently, the proteins expression of TLR8, TIRAP and MyD88 in ear homogenates also reduced obviously in AS-IV treated mice. Conclusions: Our finding indicated the disordered TLR8-mediated NF-κB pathway may play an important role in the pathogenesis of AD recurrence. AS-IV prophylactic administration in remission phase could regulate TLR8-mediated NF-κB pathway to against AD recurrence. These findings further improved our understanding of the pathogenesis of AD recurrence and the pharmacological effects of AS-IV.

show abstract

“…A meta-analysis on YuPingFeng treatment of recurrent respiratory tract infections in children also provided some insights. 28 A total of 1,236 subjects in 12 randomized control trials (RCTs) were screened, with a 4-week to 3-month treatment period and a 6–12-month observation period. Compared with traditional therapy alone, combined treatment with YuPingFeng significantly increased serum levels of IgA, IgG, IgM, and CD3 + cells, and three of the studies demonstrated that treatment with YuPingFeng reduced the frequency of recurrent respiratory tract infections in children.…”

Section: Discussionmentioning

confidence: 99%

Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study

Ma¹,

Zheng²,

Zhong³

et al. 2018

COPD

View full text Add to dashboard Cite

PurposeRecurrence of acute exacerbations has a major impact on patients with COPD. Therefore, effective prevention and treatment of exacerbation is crucial in the management of COPD, especially for patients with moderate to severe disease. This study evaluated the effectiveness of YuPingFeng granule administration in preventing exacerbation and improving symptom score, as well as its long-term (1 year) safety profile, in patients with COPD.Patients and methodsThis was a randomized, double-blind, parallel, placebo-controlled study of 240 patients from eight centers in China. Participants were eligible if they had mild to severe COPD as defined by Global Initiative for Chronic Obstructive Lung Disease, had a history of at least two COPD exacerbations or one hospitalization within the previous year, and had remained clinically stable for over 4 weeks before the study. They were randomly assigned to receive 5 g of YuPingFeng or placebo, three times per day, for 1 year. The primary end point was the exacerbation rate over 1 year, and the analysis was by intention to treat. Secondary end points included symptom score, which was assessed by COPD assessment test (CAT) score and safety profiles. This trial was registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn; registration number: ChiCTR-IPR-15007023).ResultsThe YuPingFeng group had a significantly lower exacerbation rate than the placebo group (1.15 vs 1.55; risk ratio=0.677 [95% CI 0.531–0.863]; P=0.002) and a significantly reduced risk of second exacerbation (95% CI 0.326–0.772; P=0.002). After treatment, the mean change in the CAT score in the YuPingFeng group (−4.41±7.01) differed significantly from that in the placebo group (−2.49±5.31; P=0.001). YuPingFeng was well tolerated.ConclusionYuPingFeng granules can be considered as a treatment option for COPD; this treatment prevents acute exacerbations of COPD and has a good safety profile.

show abstract

Adjuvant Treatment with Yupingfeng Formula for Recurrent Respiratory Tract Infections in Children: A Meta-analysis of Randomized Controlled Trials

Cited by 23 publications

References 15 publications

Yupingfeng San Inhibits NLRP3 Inflammasome to Attenuate the Inflammatory Response in Asthma Mice

Yupingfeng San Inhibits NLRP3 Inflammasome to Attenuate the Inflammatory Response in Asthma Mice

Astragaloside IV prophylactic administration relieves recurrent allergic atopic dermatitis

Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study

Contact Info

Product

Resources

About